Journal of the Pediatric Infectious Diseases Society
-
J Pediatric Infect Dis Soc · Apr 2020
Multicenter StudyLong-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
P1093 is an ongoing phase I/II multicenter open-label study of dolutegravir plus an optimized background regimen in age-defined pediatric cohorts; here we report the long-term safety and virologic efficacy outcomes for the oldest cohort. ⋯ NCT01302847.